TVTX vs. AXSM, AKRO, ADMA, PCVX, KRYS, RYTM, CYTK, PTCT, ZLAB, and ACAD
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Vaxcyte (PCVX), Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.
Travere Therapeutics vs. Its Competitors
Axsome Therapeutics (NASDAQ:AXSM) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
Axsome Therapeutics has a net margin of -64.39% compared to Travere Therapeutics' net margin of -82.88%. Axsome Therapeutics' return on equity of -272.80% beat Travere Therapeutics' return on equity.
Axsome Therapeutics currently has a consensus target price of $172.33, indicating a potential upside of 61.14%. Travere Therapeutics has a consensus target price of $32.14, indicating a potential upside of 121.45%. Given Travere Therapeutics' higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Axsome Therapeutics.
Axsome Therapeutics has higher revenue and earnings than Travere Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
81.5% of Axsome Therapeutics shares are owned by institutional investors. 22.4% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Axsome Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
In the previous week, Axsome Therapeutics had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 17 mentions for Axsome Therapeutics and 15 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.23 beat Axsome Therapeutics' score of 0.07 indicating that Travere Therapeutics is being referred to more favorably in the news media.
Summary
Axsome Therapeutics beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TVTX) was last updated on 7/7/2025 by MarketBeat.com Staff
Free TVTX Stock Alerts